Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy
ConclusionPolypharmacy is an independent prognostic factor in older patients with advanced NSCLC treated with ICI. Also, polypharmacy could be utilized as a simple indicator of patients ’ comorbidities and symptoms or as a predictive marker of unexpected hospitalizations during ICI treatment.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer